US peptide regulation in 2026: the HHS reclass and what it means
RFK and HHS moved most restricted peptides back to Category 1 in early 2026. Here is what that actually does, and what it does not.
In February and March 2026, the US Department of Health and Human Services, under Secretary Robert F. Kennedy Jr., issued guidance moving approximately 14 of 19 previously-restricted peptides from Category 2 back to Category 1 under FDA's compounding framework.
This was consequential. Here is the honest version of what it means.
The two categories in plain English
Under the Federal Food, Drug, and Cosmetic Act, bulk drug substances used by compounding pharmacies fall into categories:
- Category 1: substances that can be used by 503A and 503B compounding pharmacies for patient-specific prescriptions, under the standard compounding rules.
- Category 2: substances that require further evaluation before inclusion. In practice, this meant compounding pharmacies could not make preparations using these substances.
Between 2023 and early 2026, a set of peptides (including BPC-157, CJC-1295, ipamorelin, epitalon, and others) sat in Category 2. Compounding pharmacies could not serve them. US users wanting these compounds went to:
1. Research-use-only vendors (grey market) 2. International sources (mostly Thailand, UK, Australia) 3. Simply did not use them
What changed in Feb-Mar 2026
HHS moved approximately 14 of the 19 substances back to Category 1. Compounding pharmacies can now prepare these for patient-specific prescriptions again, under the standard rules.
Which peptides benefited: BPC-157, CJC-1295, ipamorelin, TB-500, MOTS-c, epitalon, GHK-Cu, and several others.
Which peptides did not: a small subset with distinct safety or potency concerns remained in Category 2 or moved to more restrictive status.
What this means in practice
For users:
1. A US licensed prescriber can write a prescription for a patient-specific compounded peptide preparation. A 503A pharmacy can fulfill it. The legal friction is now prescriber-dependent, not pharmacy-dependent. 2. This is not the same as over-the-counter. You still need a prescription. Your prescriber has to be comfortable writing it. 3. Supply chain, cold chain, and pricing are pharmacy-dependent. A good compounding pharmacy charges more than research-chem but delivers known-identity product with oversight.
For the grey market:
Research-use-only vendors still exist. Their legal status did not change. Users who want the convenience and price of that channel still have it. But the option of "go through a licensed US pharmacy" is now available for most peptides, which shifts the cost-benefit.
For telehealth clinics:
Telehealth weight-loss clinics (Hims, Ro, Henry Meds) had been offering compounded semaglutide and tirzepatide under a shortage exemption. The HHS reclass did not directly touch tirzepatide (which was never in Category 2), but the regulatory tone shift has affected how aggressively these clinics operate and what they offer.
Does this apply to tirzepatide
Tirzepatide (Mounjaro) was never in Category 2 in the same way as the peptides above. Tirzepatide is an FDA-approved drug manufactured by Eli Lilly and sold under prescription in the US. Compounded tirzepatide exists under the shortage-list exemption (503A compounding pharmacies can prepare it during a declared shortage) but its regulatory framing is distinct from the BPC-157 etc. question.
In practice, compounded tirzepatide availability in the US through telehealth has been stable through 2026 under the shortage declaration, though that declaration status evolves.
What this does not mean
It does not mean peptides are "now legal" in a new way. They were always legal for licensed prescribers to prescribe. The Category 2 issue was about what compounding pharmacies could prepare, not about personal possession.
It does not change customs enforcement. International orders of peptides still cross customs. Individual customs officers apply their own judgment. Small personal quantities have historically not been a priority target, but this is discretionary.
It does not standardize quality. A US compounding pharmacy is better regulated than a research-chem vendor, but quality still varies pharmacy to pharmacy. Verify the pharmacy you are routed through.
What we tell US users
At the bottom of the Panya result page for US-region users, we include:
A note for US visitors: peptide regulation in the US shifted in early 2026. Roughly 14 of 19 previously-restricted compounds moved from Category 2 back to Category 1, which means compounding pharmacies can dispense them again under the right conditions. The specifics depend on your state, your practitioner, and the compound.
We show you what is available and cite who is currently serving US residents. Research-use vendors operate in a grey zone that has been stable for years — we link them with that context, not as a recommendation. Your body, your call.
State-level variance
Some US states have layered additional rules on top of the federal framework. California, Texas, and a few others have specific provisions on compounded weight-loss drugs, peptide-specific consent requirements, or prescriber-scope limits.
Before your first visit with a prescriber, ask whether their state imposes any restrictions beyond the federal framework for your intended compound.
If you want a routed match
Take the quiz. We match US users to telehealth clinics and compounding pharmacies that currently serve US residents, with honest framing on the state-level variance.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.